Thursday, November 15, 2007


Topical drug may reduce recovery time for post-LASIK vision

Adding topical cyclosporine A to the standard postoperative treatment regimen may help speed visual recovery and improve final vision in patients undergoing LASIK, according to a retrospective study by California researchers.

At 1 week postop, 44.9% of eyes treated with cyclosporine achieved a visual acuity of 20/15 compared with 22.2% of control eyes, according to the study.


Cataract surgery safe in patients receiving anticoagulation therapy

Cataract surgery can be safely performed using phacoemulsification in patients with uncomplicated cataracts who receive anticoagulation therapy with warfarin, according to a prospective study by researchers in Israel.

The study is published in the November issue of American Journal of Ophthalmology.


New accommodating IOL provides excellent visual acuity, contrast sensitivity

A slightly modified fourth-generation accommodating IOL currently in clinical trials gave patients excellent intermediate and near vision, as well as good contrast sensitivity, according to John A. Hovanesian, MD. Dr. Hovanesian, MD, presented 4 to 6 months results from 60 patients who received the crystalens HD-100 (eyeonics) in one eye. Eyeonics is hoping to launch the lens a year from now, pending approval. "The new generation is clearly an improvement upon the results of the currently approved IOLs," Dr. Hovanesian said.

In his presentation, Dr. Hovanesian said that for uncorrected monocular intermediate distance vision, 80% of patients with the crystalens HD saw 20/20 or better; 93% saw 20/25; 96.6% saw 20/32 or better; and 100% saw 20/40 or better. For uncorrected monocular near visual acuity, 55% of patients saw J1 or better; 80% saw J2 or better; and 100% saw J3 or better. Contrast sensitivity also remained equal to or better than the FDA-approved crystalens AT-45.


Topical bromfenac effective in improving vision in CME patients

According to this paper:

Administering topical Xibrom (bromfenac ophthalmic solution 0.09%, Ista Pharmaceuticals) twice daily is as effective as diclofenac sodium and ketorolac tromethamine for the treatment of acute pseudophakic CME after uncomplicated phacoemulsification and posterior chamber IOL implantation.